Aurobindo Pharma today said it has received US health regulator’s approval to market anti-diabetes drug Pioglitazone Tablets in the American market. The drug firm has received approval from US Food and Drug Administration (USFDA) to manufacture and market Pioglitazone Tablets and its earlier tentatively approved combination of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, Aurobindo Pharma said in a statement. The products are ready for launch, it added. The medicines are indicated as an addition to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.
